Results 1 to 10 of about 1,395,710 (388)

The standardization of immunohistochemical detection and interpretation of CD30 expression in lymphomas [PDF]

open access: yesZhongguo aizheng zazhi, 2023
CD30 can be expressed in a variety of lymphoma subtypes, among which classical Hodgkin lymphoma (CHL) and anaplastic large cell lymphoma (ALCL) are the most common ones.
CD-Positive Lymphoma Pathology Expert Group
doaj   +1 more source

Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse

open access: yesBlood Cancer Journal, 2021
Although methotrexate (MTX) is the most widely used therapy for central nervous system (CNS) prophylaxis in patients with diffuse large B-cell lymphoma (DLBCL), the optimal regimen remains unclear.
Sabela Bobillo   +21 more
doaj   +1 more source

Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre

open access: yesBMC Cancer, 2023
Background Dihydropyrimidine dehydrogenase (DPD) is a key enzyme in the metabolism of fluoropyrimidines. Variations in the encoding DPYD gene are associated with severe fluoropyrimidine toxicity and up-front dose reductions are recommended.
David K. Lau   +16 more
doaj   +1 more source

Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma

open access: yesBlood Cancer Journal, 2022
Between 1998 and 2009, a total of 295 patients (median age 58, 53% females) with newly diagnosed early-stage follicular lymphoma (FL) were managed at Memorial Sloan Kettering Cancer Center.
Fushen Sha   +26 more
doaj   +1 more source

First experience of using Brentuximab vedotin and modified program NHL-BFM-90 in the front-line treatment of patient with anaplastic large-cell lymphoma: a case report and a review of literature [PDF]

open access: yesТерапевтический архив, 2018
Nodal anaplastic ALK-negative large cell lymphoma (nALCL, ALK-) is a Т-cell lymphoma that is characterized by aggressive clinical course and low sensitivity to СНОР (cyclophosphamide, doxorubicin, vincristine, prednisolone) and other chemotherapy regimen.
N G CHERNOVA   +10 more
doaj   +1 more source

Diffuse large B-cell lymphoma involving osseous sites: utility of response assessment by PET/CT and good longterm outcomes

open access: yesHaematologica, 2023
Osseous involvement by diffuse large B-cell lymphoma (DLBCL-bone) is a heterogeneous disease. There is limited data regarding response assessment by positron emission tomography with fluorodeoxyglucose, which may demonstrate residual avidity despite a ...
Paola Ghione   +22 more
doaj   +1 more source

Vitamin D3 receptor is highly expressed in Hodgkin's lymphoma [PDF]

open access: yes, 2012
Background: Hodkin s lymphoma is one of the most frequent lymphoma in western world. Despite an overall good prognosis some patients suffer relapsing tumors which are difficult to cure.
Benz, Alexander   +2 more
core   +2 more sources

Expression of thyroglobulin on follicular dendritic cells of thyroid mucosa-associated lymphoid tissue (MALT) lymphoma [PDF]

open access: yes, 2009
Reportedly, thyroid mucosa-associated lymphoid tissue (MALT) lymphoma is closely associated with Hashimoto's thyroiditis. However, it remains unknown which antigen is closely associated with thyroid MALT lymphoma.
Akagi, Tadaatsu   +8 more
core   +1 more source

p53 directly downregulates the expression of CDC20 to exert anti-tumor activity in mantle cell lymphoma

open access: yesExperimental Hematology & Oncology, 2023
Background Cell cycle dysregulation characterized by cyclin D1 overexpression is common in mantle cell lymphoma (MCL), while mitotic disorder was less studied. Cell division cycle 20 homologue (CDC20), an essential mitotic regulator, was highly expressed
Yingtong Chen   +9 more
doaj   +1 more source

How we treat mature B-cell neoplasms (indolent B-cell lymphomas)

open access: yesJournal of Hematology & Oncology, 2021
Mature B cell neoplasms, previously indolent non-Hodgkin lymphomas (iNHLs), are a heterogeneous group of malignancies sharing similar disease courses and treatment paradigms. Most patients with iNHL have an excellent prognosis, and in many, treatment can
Melissa Lumish   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy